ÂÜÀòÂÒÂ×

Brian Di Donato has more than 20 years of financial and leadership experience and currently serves as chief financial officer and head of strategy at Immunocore, a late-stage biotechnology company pioneering the development of a novel class of T cell receptor bispecific immunotherapies. Prior to joining Immunocore, Mr. Di Donato served as senior vice president and chief financial officer at Achillion Pharmaceuticals and held leadership roles in several financial services companies, including Morgan Stanley and UBS Securities. Mr. Di Donato holds an MBA from New York University’s Stern School of Business and B.S. degrees in biology from Penn State University and mechanical engineering from Villanova University. Mr. Di Donato also served in the U.S. Navy as an aerospace engineering officer.